A small-molecule intra-articular Wnt pathway inhibitor, SM04690, is being developed and the results of a phase IIb trial were presented at the ACR meeting by Yusuf Yazici, MD, of NYU Langone School of Medicine in New York City and Samumed, LLC, in San Diego.
Clinical Challenges: Can OA Be Stopped?
By Michael Tattory|
2018-11-07T16:27:08-04:00
November 7th, 2018|News|Comments Off on Clinical Challenges: Can OA Be Stopped?